niacinamide has been researched along with Soft Tissue Neoplasms in 7 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Soft Tissue Neoplasms: Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Phase II multi-disease randomized discontinuation trial to assess the safety and efficacy of sorafenib including patients with advanced soft tissue sarcoma (STS)." | 9.15 | Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial. ( Cupit, L; Flaherty, KT; Judson, IR; Kaye, SB; O'Dwyer, PJ; Pacey, S; Ratain, MJ; Rowinsky, EK; Xia, C, 2011) |
| "Phase II multi-disease randomized discontinuation trial to assess the safety and efficacy of sorafenib including patients with advanced soft tissue sarcoma (STS)." | 5.15 | Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial. ( Cupit, L; Flaherty, KT; Judson, IR; Kaye, SB; O'Dwyer, PJ; Pacey, S; Ratain, MJ; Rowinsky, EK; Xia, C, 2011) |
| "Sorafenib was given at a dose of 400 mg orally twice daily in 28-day cycles." | 2.74 | Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. ( Aragon-Ching, JB; Arlen, PM; Chen, CC; Dahut, WL; Draper, D; Figg, WD; Gulley, JL; Jain, L; Jones, E; Steinberg, SM; Venitz, J; Wright, JJ, 2009) |
| "Fifteen patients presented with metastases at the time of diagnosis." | 1.40 | Sorafenib in advanced, heavily pretreated patients with soft tissue sarcomas. ( Bauernhofer, T; Brämswig, K; Brodowicz, T; Girschikofsky, M; Hilbe, W; Hochreiner, G; Kühr, T; Leitgeb, C; Martel, A; Mlineritsch, B; Petzer, A; Ploner, F; Ressler, S; Romeder, F; Seebacher, V; Stöger, H; Wöll, E, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brämswig, K | 1 |
| Ploner, F | 1 |
| Martel, A | 1 |
| Bauernhofer, T | 1 |
| Hilbe, W | 1 |
| Kühr, T | 1 |
| Leitgeb, C | 1 |
| Mlineritsch, B | 1 |
| Petzer, A | 1 |
| Seebacher, V | 1 |
| Stöger, H | 1 |
| Girschikofsky, M | 1 |
| Hochreiner, G | 1 |
| Ressler, S | 1 |
| Romeder, F | 1 |
| Wöll, E | 1 |
| Brodowicz, T | 1 |
| Aragon-Ching, JB | 1 |
| Jain, L | 1 |
| Gulley, JL | 1 |
| Arlen, PM | 1 |
| Wright, JJ | 1 |
| Steinberg, SM | 1 |
| Draper, D | 1 |
| Venitz, J | 1 |
| Jones, E | 1 |
| Chen, CC | 1 |
| Figg, WD | 1 |
| Dahut, WL | 1 |
| Spector, E | 1 |
| Franklin, MJ | 1 |
| Truskinovsky, AM | 1 |
| Dudek, AZ | 1 |
| Paulino, AC | 1 |
| Pappo, A | 1 |
| Pacey, S | 1 |
| Ratain, MJ | 1 |
| Flaherty, KT | 1 |
| Kaye, SB | 1 |
| Cupit, L | 1 |
| Rowinsky, EK | 1 |
| Xia, C | 1 |
| O'Dwyer, PJ | 1 |
| Judson, IR | 1 |
| Salas, S | 1 |
| Huynh, T | 1 |
| Deville, JL | 1 |
| Duffaud, F | 1 |
| Rastogi, A | 1 |
| Bihari, C | 1 |
| Jain, D | 1 |
| Gupta, NL | 1 |
| Sarin, SK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer[NCT00090545] | Phase 2 | 46 participants (Actual) | Interventional | 2004-09-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Geometric mean exposure for sorafenib. (NCT00090545)
Timeframe: 0, 0.25, 0.50, 1, 2, 4, 6, 8, 12, and 24 hours post-dose
| Intervention | mg/L.h (Geometric Mean) |
|---|---|
| First Stage - Disease Progression | 9.76 |
| Second Stage - Increased Accrual | 18.63 |
Plasma concentration-time profile for sorafenib. (NCT00090545)
Timeframe: 0, 0.25, 0.50, 1, 2, 4, 6, 8, 12, AND 24 hours post dose
| Intervention | mg/L (Mean) |
|---|---|
| First Stage - Disease Progression | 1.28 |
| Second Stage - Increased Accrual | 2.57 |
Time from treatment start date until date of death or date last known alive. (NCT00090545)
Timeframe: Time from treatment start date until date of death or date last known alive, approximately 18.3 months.
| Intervention | Months (Median) |
|---|---|
| First Stage - Disease Progression | 18 |
| Second Stage - Increased Accrual | 18.3 |
Here is the number of participants with adverse events. For the detailed list of adverse events, see the adverse event module. (NCT00090545)
Timeframe: Date treatment consent signed to date off study, approximately 49 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| First Stage - Disease Progression | 22 |
| Second Stage - Increased Accrual | 23 |
Determine whether BAY 43-9006 when used to treat metastatic prostate cancer is associated with having 50% of Patients Progression Free at 4 Months by clinical, radiographic, and prostatic specific antigen (PSA)criteria. (NCT00090545)
Timeframe: 4 months
| Intervention | months (Median) |
|---|---|
| First Stage - Disease Progression | 1.83 |
| Second Stage - Increased Accrual | 3.7 |
Time to maximum concentration for sorafenib. (NCT00090545)
Timeframe: 0, 0.25, 0.50, 1, 2, 4, 6, 8, 12, and 24 hours post-dose
| Intervention | hours (Median) |
|---|---|
| First Stage - Disease Progression | 0.68 |
| Second Stage - Increased Accrual | 8 |
Overall response was evaluated by the RECIST. Complete Response (CR) is the disappearance of all target lesions. Partial Response (PR) is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD) is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. Stable Disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. (NCT00090545)
Timeframe: Every 2 cycles (1 cycle = 28 days)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Complete Response | Partial Response | Progressive Disease | Stable Disease | |
| First Stage - Disease Progression | 0 | 0 | 8 | 0 |
| Second Stage - Increased Accrual | 0 | 1 | 13 | 10 |
1 review available for niacinamide and Soft Tissue Neoplasms
| Article | Year |
|---|---|
[Antiangionic drugs in soft tissue sarcoma].
Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal | 2010 |
2 trials available for niacinamide and Soft Tissue Neoplasms
| Article | Year |
|---|---|
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Disease-Free Surv | 2009 |
Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Demography; Female; Humans; Male; Middle Aged | 2011 |
4 other studies available for niacinamide and Soft Tissue Neoplasms
| Article | Year |
|---|---|
Sorafenib in advanced, heavily pretreated patients with soft tissue sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Leiomyosarcoma; Male; Middle | 2014 |
Sorafenib induces partial response in metastatic medullary thyroid carcinoma.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Carcinoma, Neuroendocrine; Humans; | 2010 |
Alveolar rhabdomyosarcoma of the extremity and nodal metastasis: Is the in-transit lymphatic system at risk?
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Camptothecin; Child; Combined Mod | 2009 |
Hepatocellular carcinoma presenting with multiple bone and soft tissue metastases and atypical cytomorphological features--a rare case report.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Mal | 2013 |